CVS Health posts Q2 2026 EPS of $2.31 and raises full-year 2026 guidance
CVS Health reported second-quarter 2026 GAAP diluted EPS of $2.31, up from $0.80 a year earlier, and Adjusted EPS of $2.58, up from $1.81. The company raised its full-year 2026 GAAP EPS, Adjusted EPS and cash flow from operations guidance, citing the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the rest of the year due to elevated cost trends and possible macro headwinds.
Key points
- Q2 2026 total revenues rose 7.3% to $106.1 billion; the prior-year quarter included $833 million in legacy litigation charges that did not recur
- Full-year 2026 Adjusted EPS guidance raised to $7.90 to $8.10 from $7.30 to $7.50; GAAP diluted EPS guidance raised to $6.84 to $7.04 from $6.24 to $6.44
- Cash flow from operations guidance raised to at least $11.5 billion from at least $9.5 billion; year-to-date operating cash flow was $10.6 billion
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.